A still from the "Rromantasy" commercial (Organon) The ad ends with a final nod to the genre, with the claim that Nexplanon is “over 99% effective, no matter the fantasy.” Organon pledges $30M ...

We recently published a list of These 10 Firms Are On Fire Today. In this article, we are going to take a look at where Organon & Co.’s (NYSE:OGN) stands against other stocks that surged yesterday.

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the ...

Now, Organon — Merck’s spin-off business that focuses on women’s health — has launched a campaign celebrating romantasy’s appeal to its target audience. The recently-unveiled campaign supports ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) investors concerning the ...

Farhan Ahmed Jovan, a prominent figure on the Bangladeshi small screen, is set to make this Eid-ul-Azha particularly memorable. Not only does it mark his first Eid since marrying Sajin Ahmed ...

On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company’s dividend payout, from $0.28 to $0.02 and would “redirect those ...

PHILADELPHIA, June 03, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company ...

SAN DIEGO, May 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks ...

Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.